Innovation to Impact (I2I) at Yale
June 14, 2022
The application deadline for I2I, a fantastic, no-cost education, and enrichment opportunity, has been extended to June 30!
APPLY 
Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application
June 10, 2022
Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell (Treg) therapies for autoimmune and inflammatory disease, today announced that the U.S. 
Prescription Video Game Treatment
May 27, 2022
Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox. The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to... 
Aclarion Announces $9.4 Million Initial Public Offering
April 25, 2022
The healthcare technology company founded by UCSF researcher Jeffery Lotz, PhD, that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public... 
Video Game Improves Cognitive Symptoms
April 14, 2022
Its first product, EndeavorRx was developed by Adam Gazzaley, Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco, to help improve attention in children between the ages of 8 and 12 with attention deficit hyperactivity disorder, or ADHD. Following it... 
Exai Bio shows Its Unique RNA-based Liquid Biopsy Strategy for Early Cancer Detection
April 12, 2022
Next-generation liquid biopsy company, Exai Bio, presented data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs (oncRNAs), and the validation of artificial intelligence (AI) profiling of oncRNAs to accurately detect cancers of diverse... 
Mission Bio Launches Solid Tumor Solution on Tapestri Platform
March 31, 2022
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis launched by University of California research professor Adam Abate, today launched the Tapestri Solution for Solid Tumor Research. 
NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients
March 22, 2022
NephroSant, Inc. a biotechnology company dedicated to accelerating the assessment of early kidney damage with a mission to significantly improve global kidney health, announced the first patient has been enrolled into the Assessment of QSant™ for Underlying Allograft Rejection (AQUA) study. 
Pionyr Doses First Patient in Expansion Study
March 11, 2022
Pionyr Immunotherapeutics, a company founded by pathologist researcher Max Krummel from the University of California, is developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body's antitumor immunity by altering, or "tuning", immune cells within the tumor...